Nutrien Ltd. Stock Rises Thursday, Still Underperforms Market
Dow Jones2026/09/03 20:33This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Nutrien Ltd. NTR inched 0.04% higher to C$111.21 Thursday, in what proved to be an all-around positive trading session for the Canadian market, with the S&P/TSX Composite Index rising 1.50% to 36,633.12.
Nutrien Ltd. closed 4.9% short of its 52-week high of C$116.95, which the company reached on March 13th.
Trading volume of 1.0 M shares remained below its 50-day average volume of 1.6 M.
Data source: Dow Jones Market Data, FactSet. Data compiled September 3, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
September 03, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ido Ben-Natan: Frequent on-chain security incidents, AI agents will increase risks
BTC rebounds and breaks through 83,000 USDT, with a 24-hour decrease of 1%
Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly
The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Crypto prices
More
